Piotr J Wysocki
Overview
Explore the profile of Piotr J Wysocki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
355
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kwinta L, Konopka K, Okon K, Lobacz M, Chlosta P, Dudek P, et al.
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39858039
: Bladder cancer is a significant clinical problem with approximately 500,000 new cases worldwide annually. In approximately 25% of cases, disease is diagnosed at a stage of invasion of the...
2.
Gamrat A, Rzepka E, Ciszek K, Wysocki P, Hubalewska-Dydejczyk A, Gilis-Januszewska A
Pol Arch Intern Med
. 2024 May;
134(7-8).
PMID: 38809414
No abstract available.
3.
Knetki-Wroblewska M, Dziadziuszko R, Jankowski T, Krawczyk P, Bryl M, Stencel K, et al.
Front Oncol
. 2024 Feb;
14:1341084.
PMID: 38322415
Introduction: Pembrolizumab combined with chemotherapy has become the standard of care for patients with non-small-cell lung cancer (NSCLC) and the expression of programmed death ligand 1 (PD-L1) in <50% of...
4.
Potocki P, Wisniowski R, Haus D, Chowaniec Z, Kozaczka M, Kustra M, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686636
Anti-EGFR antibodies combined with chemotherapy doublets are a cornerstone of the upfront treatment of colorectal cancer. RAS and BRAF mutations are established negative predictive factors for such therapy. The primary...
5.
Potocki P, Wojcik P, Chmura L, Goc B, Fedewicz M, Bielanska Z, et al.
Int J Mol Sci
. 2023 May;
24(10).
PMID: 37240418
BRAF V600E and KRAS mutations that occur in colorectal cancer (CRC) define a subpopulation of patients with an inferior prognosis. Recently, the first BRAF V600E-targeting therapy has been approved and...
6.
Buda-Nowak A, Kwinta L, Potocki P, Michalowska-Kaczmarczyk A, Slowik A, Konopka K, et al.
J Clin Med
. 2023 Feb;
12(4).
PMID: 36835886
Background: Breast cancer, with 2.3 million new cases and 0.7 million deaths every year, represents a great medical challenge worldwide. These numbers confirm that approx. 30% of BC patients will...
7.
Wysocki P, Lobacz M, Potocki P, Kwinta L, Michalowska-Kaczmarczyk A, Slowik A, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831410
Patients with advanced ovarian cancer (OC) have a detrimental prognosis. The options for systemic treatment of advanced OC in later lines of treatment are limited by the availability of active...
8.
Wysocki P, Lubas M, Wysocka M
J Clin Med
. 2022 May;
11(10).
PMID: 35628979
Despite the significant expansion of the therapeutic armamentarium associated with the introduction of novel endocrine therapies, cytotoxic agents, radiopharmaceuticals, and PARP inhibitors, progression of metastatic castration-resistant prostate cancer (mCRPC) beyond...
9.
Konopka K, Fraczek P, Lubas M, Micek A, Kwinta L, Streb J, et al.
J Clin Med
. 2022 Mar;
11(5).
PMID: 35268305
Background: Interplay between non-specific inflammatory reaction and tumor microenvironment in gastric cancer (GC) can be measured indirectly by assessing fluctuations in concentration of platelets. Cytotoxic chemotherapy affects these morphotic elements...
10.
Powles T, Yuen K, Gillessen S, Kadel 3rd E, Rathkopf D, Matsubara N, et al.
Nat Med
. 2022 Jan;
28(1):144-153.
PMID: 35013615
Early clinical data indicate that some patients with castration-resistant prostate cancer may benefit from program death ligand-1 (PD-L1) inhibition, especially with enzalutamide. The IMbassador250 trial (no. NCT03016312) enrolled 759 men...